De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Jafron BiomedicalLtd Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Fan Dong

Algemeen directeur

CN¥3.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	14.1yrs
Eigendom CEO	46.4%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

Oct 02

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Sep 09

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Aug 25

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04

CEO

Fan Dong (54 yo)

14.1yrs

Tenure

CN¥3,741,000

Compensatie

Mr. Fan Dong serves as Chairman of Board of Directors and General Manager at Jafron Biomedical Co., Ltd. He serves as Director since April 27, 2023 at Jafron Biomedical Co.,Ltd. He served as Company Secret...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Fan Dong	Chairman of Board of Directors & GM	no data	CN¥3.74m	46.39% CN¥ 11.2b
Xueyun Liao	Director & Financial Director	1.5yrs	CN¥500.50k	0.019% CN¥ 4.6m
De Zhi Li	Deputy General Manager	no data	CN¥865.40k	0.46% CN¥ 111.4m
Xian Min Tang	Deputy GM & Director	no data	CN¥2.65m	2.79% CN¥ 672.0m
Aijun Wu	Deputy General Manager	4.4yrs	CN¥2.44m	0.032% CN¥ 7.6m
Rui Wang	General Manager	1.1yrs	CN¥510.40k	geen gegevens
Cong Huang	Board Secretary	2.1yrs	CN¥455.20k	0.00045% CN¥ 108.3k

1.8yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300529 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Fan Dong	Chairman of Board of Directors & GM	14.1yrs	CN¥3.74m	46.39% CN¥ 11.2b
Xueyun Liao	Director & Financial Director	less than a year	CN¥500.50k	0.019% CN¥ 4.6m
Xian Min Tang	Deputy GM & Director	14.1yrs	CN¥2.65m	2.79% CN¥ 672.0m
Claudio Ronco	Member of Global Advisory Board	3.3yrs	geen gegevens	geen gegevens
Feng Li	Non-Independent Director	4.5yrs	CN¥1.08m	0.10% CN¥ 24.1m
Xiaohong Peng	Chairman of Supervisory Board	4.5yrs	geen gegevens	geen gegevens
Wen Lei	Non-Independent Director	4.5yrs	CN¥177.20k	geen gegevens
Rinaldo Bellomo	Member of Global Advisory Board	3.3yrs	geen gegevens	geen gegevens
Thomas Rimmelé	Member of Global Advisory Board	3.3yrs	geen gegevens	geen gegevens
John Prowle	Member of Global Advisory Board	3.3yrs	geen gegevens	geen gegevens
Antoine Schneider	Member of Global Advisory Board	3.3yrs	geen gegevens	geen gegevens
Olivier Joannes-Boyau	Member of Global Advisory Board	3.3yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300529 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Jafron BiomedicalLtd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

High number of new directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Investor sentiment deteriorates as stock falls 20%

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

New minor risk - Share price stability

Jafron Biomedical Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 17%

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Now 20% overvalued after recent price rise

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 15%

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Consensus revenue estimates fall by 13%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

Price target decreased to CN¥56.67

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥73.99

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥84.63

New 90-day low: CN¥64.16

Market pulls back on stock over the past week

Price target raised to CN¥95.66

New 90-day high: CN¥78.75

Price target raised to CN¥52.96

Third quarter earnings released

Jafron Biomedical Co.,Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day low: CN¥64.37

New 90-day high - CN¥77.44

Earnings released

Jafron Biomedical Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure